Spyre Therapeutics (SYRE) said Monday it started an underwritten public offering of up to $200 million of shares or pre-funded warrants.
Underwriters will be given an option for a 30-day period to buy up to an additional $30 million of shares, the company said.
All of the shares and warrants will be sold by Spyre, the company said, adding the offering is subject to market conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.